- Home
- MTA vs CSTL Comparison
MTA vs CSTL Comparison
Compare MTA & CSTL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | MTA | CSTL |
|---|---|---|
| Founded | 1983 | 2007 |
| Country | Canada | United States |
| Employees | N/A | N/A |
| Industry | | Medical Specialities |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 902.2M | 722.8M |
| IPO Year | 2017 | 2019 |
Fundamental Metrics
Financial Performance| Metric | MTA | CSTL |
|---|---|---|
| Price | $7.60 | $35.07 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 10 |
| Target Price | N/A | ★ $46.70 |
| AVG Volume (30 Days) | 327.9K | ★ 329.3K |
| Earning Date | 08-13-2026 | 11-05-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $344,229,000.00 |
| Revenue This Year | $79.53 | $8.68 |
| Revenue Next Year | $57.28 | $12.08 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 3.66 |
| 52 Week Low | $5.95 | $17.72 |
| 52 Week High | $11.60 | $44.28 |
Technical Indicators
Market Signals| Indicator | MTA | CSTL |
|---|---|---|
| Relative Strength Index (RSI) | 31.46 | 52.50 |
| Support Level | $7.08 | $33.90 |
| Resistance Level | $7.21 | $37.42 |
| Average True Range (ATR) | 0.32 | 1.76 |
| MACD | -0.01 | 0.24 |
| Stochastic Oscillator | 5.04 | 49.18 |
Price Performance
Historical ComparisonAbout MTA Metalla Royalty & Streaming Ltd.
Metalla Royalty & Streaming Ltd is a precious metals royalty and streaming company that engages in the acquisition and management of precious metal and copper royalties and streams. It generates revenue from royalties, streams, and other interests. Geographically, the company generates revenue from Australia, Brazil, Mexico, and the USA.
About CSTL Castle Biosciences Inc.
Castle Biosciences Inc is a molecular diagnostics company. The group provides test solutions for the diagnosis and treatment of dermatologic cancers, Barrett's esophagus (BE), and uveal melanoma. The product portfolio of the company includes DecisionDx-Melanoma, a risk stratification gene expression profile (GEP) test; DecisionDx-SCC, a risk stratification test for cutaneous squamous cell carcinoma; MyPath Melanoma, a diagnostic GEP test for use in patients with difficult-to-diagnose melanocytic lesions; and TissueCypher, a test to predict future development of progression of high-grade dysplasia and/or esophageal cancer. The company derives revenues through the delivery of test reports for its molecular diagnostic tests.